Matinas Biopharma Holdings, Inc.

0.18 USD
+0.01 (+3.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Matinas Biopharma Holdings, Inc. stock is down -7.5% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 May’s closed higher than April.

About Matinas Biopharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.